NASDAQ: LBPH - Longboard Pharmaceuticals, Inc.

Yield per half year: +238.76%
Sector: Healthcare

Longboard Pharmaceuticals, Inc.

Underestimation

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
P/E
0/10
0 48.77 -100% -3.32 -100%
P/S 0 33.76 -100%
P/BV 3.44 4.82 -28.58%
P/FCF 0 61 -100%
Ev/Ebitda -2.24 -22.15 -89.89%
Ev/S 0 22.56 -100%
Ev/FCF -2.5 68.78 -103.63%
E/P 0 0.0178 -100%

Efficiency

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
Ebitda margin
0/10
0 4.98 -100% 0 0%
ROE -132.99 9.61 -1483.6%
ROA -107.35 0.3443 -31282.17%
ROIC 0 7.63 -100%
ROS 0 -25.17 -100%
ROCE -138.7 15.35 -1003.54%

Debt

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
Debt/Ebitda
10/10
-0.0084 -3.68 -99.77% -0.013 -35.72%
Nеt Debt/Ebitda 0.2441 -3.44 -107.1%
Debt/Ratio 0.0094 0.1985 -95.28%
Debt/Equity 52.78 1.66 3075.1%
Debt/Net Income -0.0087 10.32 -100.08%

Dividends

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
Dividend yield
0/10
0 0.5468 -100% 0 0%
Number of years of dividend growth 0 0.2632 -100%
DSI 0 0.2193 -100%
Average dividend growth 0 0.4414 -100%
Average percentage for 5 years 0 0.4968 -100%
Average percentage for payments 0 43.56 -100%
Difference from average difference in sector -0.5468

Growth impulse

Parameter Grade Value Sector average Difference with sector, %
Growth impulse Revenue in 5 years
0/10
0 -56.89 -100%
Growth impulse Ebitda in 5 years 294.13 -54.68 -637.91%
Growth impulse Net Income in 5 years 277.93 -58.33 -576.48%
Growth impulse FCF in 5 years 1396.12 -49.48 -2921.58%
Growth impulse EPS in 5 years 181.33 -32.41 -659.49%
IP Score
3.83/10

Similar companies

Alexion

ABIOMED

Amgen

Gilead Sciences

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription